Antiviral Ranpirnase TMR-001 Inhibits Rabies Virus Release and Cell-to-Cell Infection In Vitro
Currently, no rabies virus-specific antiviral drugs are available. Ranpirnase has strong antitumor and antiviral properties associated with its ribonuclease activity. TMR-001, a proprietary bulk drug substance solution of ranpirnase, was evaluated against rabies virus in three cell types: mouse neur...
Main Authors: | Todd G. Smith, Felix R. Jackson, Clint N. Morgan, William C. Carson, Brock E. Martin, Nadia Gallardo-Romero, James A. Ellison, Lauren Greenberg, Thomas Hodge, Luis Squiquera, Jamie Sulley, Victoria A. Olson, Christina L. Hutson |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-02-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/12/2/177 |
Similar Items
-
The therapeutic potential of the novel ribonuclease ranpirnase (Onconase®) in the treatment of malignant mesothelioma
by: Luciano Mutti, et al.
Published: (2011-12-01) -
The therapeutic potential of the novel ribonuclease ranpirnase (Onconase®) in the treatment of malignant mesothelioma
by: Luciano Mutti, et al.
Published: (2011-12-01) -
Ranpirnase (OKG-0301), a Novel Ribonuclease, Demonstrates Antiviral Activity against Adenovirus in the Ad5/NZW Rabbit Ocular Replication Model
by: Eric G. Romanowski, et al.
Published: (2022-12-01) -
Human Rabies Treatment—From Palliation to Promise
by: Marian Lacy, et al.
Published: (2024-01-01) -
Anti-rabies vaccines applied in the Russian Federation and perspectives for their improvement
by: A. L. Elakov
Published: (2022-05-01)